Form D · Other Technology
ImmunoVec, Inc.
Los Angeles, CA · CIK 0001914272
Offering snapshot reported Jul 14, 2026 · SEC filing
- Reported sold
- $12.7M Offering amount: $15M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 29, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 14, 2026 | Initial | $12,705,822 | No comparison | 10 | SEC filing |
| Mar 1, 2022 | Initial | $4,298,958 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-590784
Preferred Stock and Common Stock issuable upon conversion thereof. Total Offering Amount and Total Amount Sold include conversion of the previously issued convertible securities.
Source: Form D, filed Jul 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglass Lorenzen | Director, Executive, Promoter |
| Chris Lucas | Director |
| Ryan Wong | Director, Executive |
| Dillon Woodward | Director |
| William Woodward | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
3435 Wilshire Blvd Suite 2700 84
Los Angeles, CA, 90010
Los Angeles, CA, 90010